

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/579,609	Applicant: James Empfield, et al
371 Filing Date: May 17, 2006	Attorney Docket No.: 101289-1P US/NS
Examiner: Rahmani, Niloofar	Group Art Unit : 1625
Customer No.: 22466	Confirmation No.: 3543
Title: 4- Substituted Imidazoles	

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants bring to the attention of the Examiner copending US application no. 10/579,608 filed May 17, 2006 (simultaneously with the present application). US 10/579,608 has not yet published, and no Office Action on the merits has been mailed. Applicants are noting this application in satisfaction of their duty of candor with the Office under 37 C.F.R. § 1.56.

US 10/579,608 is listed on the enclosed Form PTO/SB/08a. Applicants respectfully request that the Examiner initial the form to show the co-pending application has been considered on the record.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114.

It is respectfully requested that the application listed on the attached Form PTO/SB/08a, and other information contained herein, be considered by the Examiner and made of record in this application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to Deposit Account No. 260166, referencing Attorney Docket No. 101289-1P US/NS.

Respectfully submitted,



Name: Michael A. Patané
Dated: December 4, 2007

Reg. No.: 42,982
Phone No.: 302.885.3949
Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437

Enclosures: Form PTO/SB/08a